CompletedPhase 2NCT00516412

Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

Studying Mantle cell lymphoma

Last synced from ClinicalTrials.gov May 14, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Swiss Cancer Institute
Principal Investigator: Christoph Renner, MD
UniversitaetsSpital Zuerich
Intervention: everolimus(drug)
Enrollment: 35 enrolled
Eligibility: 18 years · All sexes
Timeline: 2007 – 2012

Study locations (21)

CHU de Grenoble - Hopital de la Tronche, Grenoble, France
Hopital Haut Leveque, Pessac, France
Centre Hospitalier Universitaire Bretonneau de Tours, Tours, France
Institut Gustave Roussy, Villejuif, France
University of Bologna Medical School, Bologna, Italy
European Institute of Oncology, Milan, Italy
Hirslanden Klinik Aarau, Aarau, Switzerland
Kantonsspital Baden, Baden, Switzerland
Universitaetsspital-Basel, Basel, Switzerland
Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
Inselspital Bern, Bern, Switzerland
Kantonsspital Graubuenden, Chur, Switzerland
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Kantonsspital Olten, Olten, Switzerland
Kantonsspital - St. Gallen, Sankt Gallen, Switzerland
+6 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00516412 on ClinicalTrials.gov

Other trials for Mantle cell lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Mantle cell lymphoma →

← Back to all trials